476 related articles for article (PubMed ID: 21415162)
21. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.
Wu E; Greenberg PE; Yang E; Yu A; Erder MH
Curr Med Res Opin; 2008 Sep; 24(9):2587-95. PubMed ID: 18674407
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
Hemels ME; Kasper S; Walter E; Einarson TR
Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745
[TBL] [Abstract][Full Text] [Related]
23. Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study.
Li C; Chen L; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Wang Z; Qian J
PLoS One; 2020; 15(4):e0232226. PubMed ID: 32353006
[TBL] [Abstract][Full Text] [Related]
24. Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study.
McIntyre RS; Prieto R; Schepman P; Yeh YC; Boucher M; Shelbaya A; Chambers R; Gao X; Pappadopulos E
Curr Med Res Opin; 2019 Dec; 35(12):2169-2177. PubMed ID: 31370711
[No Abstract] [Full Text] [Related]
25. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
26. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
Kongsakon R; Bunchapattanasakda C
J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
[TBL] [Abstract][Full Text] [Related]
27. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
Köhler-Forsberg O; Larsen ER; Buttenschøn HN; Rietschel M; Hauser J; Souery D; Maier W; Farmer A; McGuffin P; Aitchison KJ; Uher R; Mors O
Br J Psychiatry; 2019 Aug; 215(2):494-501. PubMed ID: 30698114
[TBL] [Abstract][Full Text] [Related]
28. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
[TBL] [Abstract][Full Text] [Related]
29. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
30. Escitalopram (Lexapro) for depression.
Masilamani S; Ruppelt SC
Am Fam Physician; 2003 Dec; 68(11):2235-6. PubMed ID: 14677669
[TBL] [Abstract][Full Text] [Related]
31. Escitalopram: a review of its use in the management of major depressive disorder.
Murdoch D; Keam SJ
Drugs; 2005; 65(16):2379-404. PubMed ID: 16266205
[TBL] [Abstract][Full Text] [Related]
32. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.
Perlis RH; Patrick A; Smoller JW; Wang PS
Neuropsychopharmacology; 2009 Sep; 34(10):2227-36. PubMed ID: 19494805
[TBL] [Abstract][Full Text] [Related]
33. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
34. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
35. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
36. Spotlight on escitalopram in the management of major depressive disorder.
Murdoch D; Keam SJ
CNS Drugs; 2006; 20(2):167-70. PubMed ID: 16478291
[TBL] [Abstract][Full Text] [Related]
37. The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis.
Culpepper L; Martin A; Nabulsi N; Parikh M
Adv Ther; 2024 May; 41(5):1860-1884. PubMed ID: 38466558
[TBL] [Abstract][Full Text] [Related]
38. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
39. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
